

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.


Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James FREDDO
Art Unit	1614
Examiner Name	To be Assigned.
Attorney Docket Number	PC25881A US

**Supplemental**  
**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SG	AA	HU-LOWE, D., et al., "Pharmacological Activities of AG013736, a Small Molecule Inhibitor of VEGF/PDGR Receptor Tyrosine Kinases," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , March 2002, p. 1082, Vol. 43	
SG	AB	LAIRD, D.A., et al., "Small Molecule Tyrosine Kinase Inhibitors: Clinical Development of Anticancer Agents," <i>Expert Opinion on Investigational Drugs</i> , January 2003, pp. 51-64, 01, Vol. 12, No. 1	
SG	AC	MARME, D., "The Impact of Anti-angiogenic Agents on Cancer Therapy," <i>J. Cancer Res. Clin. Oncol.</i> , November 2003, pp. 607 - 620, Vol. 129, No. 11.	
SG	AD	SAKI, P., et al. "AG-013736, a Potent VEGF/PDGF Receptor Tyrosine Kinase Inhibitor, is Active Against Lymphoma Growth and Chemotherapy-induced Vasculogenesis," <i>Blood</i> , November 16, 2003, p. 649a, Vol. 102, No. 11.	
SG	AE	WICKMAN, G., et al., "Further Characterization of the Potent VEGF/PDGF Receptor Tyrosine Kinase Inhibitor AG-013736 in Preclinical Tumor Models for its Antiangiogenesis and Antitumor Activity," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , July 2003, pp. 752-753, Vol. 44., 2 <sup>nd</sup> ed.	
SG	AF	WILMES, L.J., et al., "AG -013736, a Novel VEGFR TK Inhibitor, Suppresses Tumor Growth and Vascular Permeability in Human BT474 Breast Cancer Xenografts in Nude Mice," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , July 2003, p. 751, Vol. 44. 2 <sup>nd</sup> ed.	

EXAMINER:

/Shirley Gembeh/

DATE CONSIDERED:


08/08/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James Freddo et al.
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	PC25581A

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
SG	AA	5,587,458	12/24/1996	King et al.	
	AB	5,747,498	05/05/1998	Schnur et al.	
	AC	5,792,783	08/11/1998	Tang et al.	
	AD	5,834,504	11/10/1998	Tang et al.	
	AE	5,861,510	01/19/1999	Piscopio et al.	
	AF	5,863,949	01/26/1999	Robinson et al.	
	AG	5,877,305	03/02/1999	Huston et al.	
	AH	5,883,113	03/16/1999	Tang et al.	
	AI	5,886,020	03/23/1999	Tang et al.	
	AJ	6,531,491	03/11/2003	Kania et al.	
SG	AK	6,534,524	03/18/2003	Kania et al.	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
SG	AL	EP606,046	12/21/1993	Novartis AG		
SG	AM	EP780,386	12/10/1996	F. Hoffmann-La Roche AG		
SG	AN	EP931,788	12/16/1998	Pfizer Limited		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

JUL 02 2004

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James Freddo et al.
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	PC25581A

SG	AO	WO90/05719	05/31/1990	British Bio-Technology Limited	
	AP	WO95/19970	07/27/1995	Warner-Lambert Company	
	AQ	WO95/21613	08/17/1995	Sugen, Inc.	
	AR	WO96/14843	05/23/1996	Cor Therapeutics, Inc.	
	AS	WO96/27583	09/12/1996	Pfizer Inc.	
	AT	WO96/33172	10/24/1996	Pfizer Inc.	
	AU	WO97/13760	04/17/1997	Glaxo Group Limited	
	AV	WO97/22596	06/26/1997	Zeneca Limited	
	AW	WO98/02434	01/22/1998	Glaxo Group Limited	
	AX	WO98/02437	01/22/1998	Glaxo Group Limited	
	AY	WO98/02438	01/22/1998	Glaxo Group Limited	
	AZ	WO98/03516	01/29/1998	Pfizer Inc.	
	BA	WO98/07697	02/26/1998	Pfizer Inc.	
	BB	WO98/14451	04/09/1998	Novartis AG	
	BC	WO98/30566	07/16/1998	Pfizer Inc.	
	BD	WO98/33768	08/06/1998	Pfizer Products Inc.	
	BE	WO98/34915	08/13/1998	Pfizer Inc.	
	BF	WO98/34918	08/13/1998	Pfizer Inc.	
✓	BG	WO98/50356	11/12/1998	Sugen, Inc.	
SG	BH	WO98/54093	12/03/1998	Merck & Co., Inc.	

EXAMINER: /Shirley Gembeh/

DATE CONSIDERED: 08/08/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James Freddo et al.
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	PC25581A

SG	BI	WO99/10349	03/04/1999	Zeneca Limited	
	BJ	WO99/16755	04/08/1999	Merck & Co., Inc.	
	BK	WO99/24440	05/20/1999	Pfizer Products Inc.	
	BL	WO99/29667	06/17/1999	Pfizer Inc.	
	BM	WO99/35132	07/15/1999	Glaxo Group Limited	
	BN	WO99/35146	07/15/1999	Glaxo Group Limited	
	BO	WO99/52889	10/21/1999	Pfizer Products Inc.	
	BP	WO99/52910	10/21/1999	Pfizer Products Inc.	
	BQ	WO99/61422	12/02/1999	Sugen, Inc.	
	BR	WO00/37107	06/29/2000	G.D. Searle & Co.	
	BS	WO00/38665	07/06/2000	G.D. Searle & Co.	
	BT	WO00/38715	07/06/2000	G.D. Searle & Co.	Not considered
	BU	WO00/38716 A1	07/06/2000	G.D. Searle & Co.	Corrected Version
	BV	WO00/38717	07/06/2000	G.D. Searle & Co.	
	BW	WO00/38718	07/06/2000	G.D. Searle & Co.	
	BX	WO00/38719	07/06/2000	G.D. Searle & Co.	
✓	BY	WO00/38730	07/06/2000	G.D. Searle & Co.	
SG	BZ	WO00/38786	07/06/2000	G.D. Searle & Co.	

**NON PATENT LITERATURE DOCUMENTS**

EXAMINER:

/Shirley Gembeh/

DATE CONSIDERED:

08/18/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James Freddo et al.
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	PC25581A

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SG	CA	JEFFREY, Phillip D. et al., "Mechanism of CDK Activation Revealed by the Structure of a CyclinA-CDK2 Complex," <i>Nature</i> , 1995, 376, 313-320.	
SG	CB	MOHAMMADI, M. et al., "Identification of Six Novel Autophosphorylation Sites on Fibroblast Growth Factor.....Transduction," 1996, 16:3, 977-989.	
SG	CC	PARAST, C. et al, "Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular....Angiogenesis," <i>Biochemistry</i> , 1998, 37, 16788-16801.	
SG	CD	ROSENBLATT, Jody et al., "Purification and Crystallization of Human Cyclin-dependent Kinase 2," <i>Journal of Molecular Biology</i> , 1993, 230, 1317-1319.	

EXAMINER:	/Shirley Gembeh/	DATE CONSIDERED:	08/18/2006
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="http://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p>			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Second Supplemental  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James FREDDO
Art Unit	1614
Examiner Name	To be Assigned.
Attorney Docket Number	PC25881A US

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SG	AA	Kaban, K., et al "Angiogenesis as a target for cancer therapy" <i>Hematology/Oncology Clinics of North America</i> , 2002, p. 1125-1171, vol. 16,	

EXAMINER: /Shirley Gembeh/

DATE CONSIDERED: 08/08/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.